MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 2, 1996, Pages 362-366

  Visalli, M A ^a   Jacobs, M R ^b   Appelbaum, P C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFOTAXIME; CIPROFLOXACIN; IMIPENEM; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0030049977     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.2.362     Document Type: Article

References (23)

1. Appelbaum, P. C. 1992. Antimicrobial resistance in Streptococcus pneumoniae - an overview. Clin. Infect. Dis. 15:77-83
2. Block, S., J. Hedrick, P. Wright, R. Finger, R. Leggiadro, M. Appleton, S. Kahn, and R. Hutcheson. 1994. Drug-resistant Streptococcus pneumoniae - Kentucky and Tennessee, 1993. Morbid. Mortal. Weekly Rep. 43:23-25, 31
3. Breiman, R. F., J. C. Butler, F. C. Tenover, J. A. Elliott, and R. R. Facklam. 1994. Emergence of drug resistant pneumococcal infections in the United States. JAMA 271:1831-1835.
4. Friedland, I. R., and G. S. Istre. 1992. Management of penicillin-resistant pneumococcal infections. Pediatr. Infect. Dis. J. 11:433-435.
5. Friedland, I. R., and G. H. McCracken, Jr. 1994. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N. Engl. J. Med. 331:377-382.
6. Jacobs, M. R. 1992. Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae. Clin. Infect Dis. 15:119-127
7. Jolley, A., J. M. Andrews, N. Brenwald, and R. Wise. 1993. The in-vitro activity of a new highly active quinolone, DU-6859a. J Antimicrob. Chemother 32:757-763.
8. Korten, V., J. F. Tomayko, and B. E. Murray. 1994. Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci. Antimicrob. Agents Chemother 38:611-615.
9. Marshall, S. A., and R. N. Jones. 1993. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone Antimicrob Agents Chemother. 37:2747-2753.
10. Marshall, S. A., R. N. Jones, P. R. Murray, J. A. Washington, S. D. Allen, E. H. Gerlach, and M. E. Erwin. 1993. In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5,086 recent clinical isolates. J. Antimicrob. Chemother. 32:877-884
11. McDougal, L. K., R. Facklam, M. Reeves, S. Hunter, J. M. Swenson, B. C. Hill, and F. C. Tenover. 1992. Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States. Antimicrob. Agents Chemother. 36:2176-2184.
12. Munoz, R., J. M. Musser, M. Crain, D. E. Briles, A. Marton, A. J. Parkinson, U. Sorensen, and A. Tonmsz. 1992. Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clin. Infect. Dis. 15:112-118.
13. Nakashima, M., T. Uematsu, K. Kosuge, K. Umemura, H. Hakusui, and M. Tanaka. 1995 Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother. 39:170-174.
14. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. Approved standard. NCCLS publication no. M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
15. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1994. Study of comparative antipneumococcal activities of penicillin G. RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob. Agents Chemother 38:2065-2072.
16. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1995. Activity of CP 99,219 compared to DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J. Antimicrob. Chemother. 35:230-232.
17. Sato, K., K. Hoshino, M. Tanaka, I. Hayakawa, and Y. Osada. 1992. Antimicrobial activity of DU-6859a, a new potent fluoroquinolone, against clinical isolates. Antimicrob. Agents Chemother. 36:1491-1498
18. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1992. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, Win 57273, ofloxacin, and ciprofloxacin. Antimicrob. Agents Chemother 36:856-359.
19. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1994 Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob. Agents Chemother. 38:898-900.
20. Spangler, S. K., M. R. Jacobs, G. A. Pankuch, and P. C. Appelbaum. 1993. Susceptibility of 170 penicillin-susceptible and -resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. J. Antimicrob. Chemother. 31:273-280
21. Spika, J. S., R. R. Facklam, B. D. Plikaytis, M. J. Oxtoby, and the Pneumococcal Surveillance Working Group. 1991. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. J. Infect. Dis. 163: 1273-1278.
22. Tweardy, D. J., M. R. Jacobs, and W. T. Speck. 1983. Susceptibility of penicillin-resistant pneumococci to eighteen antimicrobials: implications for treatment of meningitis. J Antimicrob. Chemother. 12:133-139.
23. Viladrich, P. F., F. Gudiol, J. Liñares, R. Pallarés, I. Sabaté, G. Rufí, and J. Ariza. 1991. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob. Agents Chemother. 35:2467-2472.